Erasca Inc. Common Stock vs Micron Technology, Inc. — how do they compare? Erasca Inc. Common Stock trades at $16.03 (market cap $5.40B), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 216.7× Erasca Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 0 Days and Micron Technology, Inc. for 48 Days on average.
| ERAS | MU | |
|---|---|---|
Market Cap | $5.40B | $1.17T |
Volume | 9,533,185 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $22.47 | $1.21K |
52-Week Low | $2.20 | $181.60 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $5.18B | $1.13T |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Micron Technology (MU) trades at $1,035.84, down 4.79% today, but maintains strong bullish momentum with 500% gains over the past year. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $33.42 versus $31.77, and maintains impressive profitability with 63.8% net income margin. Technical indicators remain bullish overall despite recent pullback, with support at $1,020 and resistance at $1,064. The company's strategic customer agreements covering 35% of revenue through 2030 provide visibility into future growth.
Micron presents compelling investment potential driven by AI memory demand surge and strong financial performance, though risks include cyclical industry exposure and potential growth deceleration. Analyst consensus remains strongly bullish with 82.9% buy ratings and $1,590 price target, representing 53% upside. The stock's valuation at 13.94 P/E appears reasonable given projected revenue growth to $133.2B in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →